Integra Lifesciences Holdings Corp
IART11.260USD
+0.380+3.49%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
876.42MMarket Cap
LossP/E TTM
More Details of Integra Lifesciences Holdings Corp Company
Integra LifeSciences Holdings Corporation is a global medical technology company. The Company manufactures and sells medical technologies and products in two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). The CSS segment consists of technologies and instrumentation used for a range of specialties, such as neurosurgery, neurocritical care and otolaryngology. The CSS business consists of a portfolio of brands, such as Codman, DuraGen, DuraSeal, CUSA, Mayfield, Bactiseal, and Certas Plus, which are used for the management of multiple disease states, including brain tumors, traumatic brain injury, hydrocephalus and other neurological conditions. It provides instruments that are used in precision, specialty and general surgical procedures. The TT segment is focused on three main areas: complex wound surgery, surgical reconstruction and peripheral nerve repair. The TT segment offers skin and wound repair, plastics and surgical reconstruction products, and others.
Integra Lifesciences Holdings Corp Info
Ticker SymbolIART
Company nameIntegra Lifesciences Holdings Corp
IPO dateAug 16, 1995
CEOPoul (Mojdeh)
Number of employees4396
Security typeOrdinary Share
Fiscal year-endAug 16
Address1100 Campus Road
CityPRINCETON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code08540
Phone16092750500
Websitehttps://www.integralife.com/
Ticker SymbolIART
IPO dateAug 16, 1995
CEOPoul (Mojdeh)
Company Executives of Integra Lifesciences Holdings Corp
Name
Name/Position
Position
Shareholding
Change
Mr. Christian S. (Chris) Schade
Mr. Christian S. (Chris) Schade
Independent Director
Independent Director
90.03K
+26531.00%
Dr. Keith Bradley, Ph.D.
Dr. Keith Bradley, Ph.D.
Independent Director
Independent Director
89.14K
+19200.00%
Ms. Lea Daniels Knight
Ms. Lea Daniels Knight
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
58.58K
-2561.00%
Mr. Jeffrey Mosebrook
Mr. Jeffrey Mosebrook
Senior Vice President - Finance, Principal Accounting Officer
Senior Vice President - Finance, Principal Accounting Officer
35.79K
-4282.00%
Mr. Harvinder Singh
Mr. Harvinder Singh
Executive Vice President, President - International Business
Executive Vice President, President - International Business
21.94K
+8684.00%
Dr. Stuart M. Essig, Ph.D.
Dr. Stuart M. Essig, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Robert T. Davis, Jr.
Mr. Robert T. Davis, Jr.
Executive Vice President, President - Tissue Technologies
Executive Vice President, President - Tissue Technologies
--
--
Ms. Barbara B. Hill
Ms. Barbara B. Hill
Independent Presiding Director
Independent Presiding Director
--
--
Mr. Eric I. Schwartz
Mr. Eric I. Schwartz
Executive Vice President, Chief Legal Officer, Secretary
Executive Vice President, Chief Legal Officer, Secretary
--
--
Mr. Michael J. Mcbreen
Mr. Michael J. Mcbreen
Executive Vice President, President - Codman Specialty Surgical
Executive Vice President, President - Codman Specialty Surgical
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Christian S. (Chris) Schade
Mr. Christian S. (Chris) Schade
Independent Director
Independent Director
90.03K
+26531.00%
Dr. Keith Bradley, Ph.D.
Dr. Keith Bradley, Ph.D.
Independent Director
Independent Director
89.14K
+19200.00%
Ms. Lea Daniels Knight
Ms. Lea Daniels Knight
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
58.58K
-2561.00%
Mr. Jeffrey Mosebrook
Mr. Jeffrey Mosebrook
Senior Vice President - Finance, Principal Accounting Officer
Senior Vice President - Finance, Principal Accounting Officer
35.79K
-4282.00%
Mr. Harvinder Singh
Mr. Harvinder Singh
Executive Vice President, President - International Business
Executive Vice President, President - International Business
21.94K
+8684.00%
Dr. Stuart M. Essig, Ph.D.
Dr. Stuart M. Essig, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Revenue Breakdown
Currency: USDUpdated: Tue, Jan 6
Currency: USDUpdated: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Neurosurgery
201.56M
50.13%
Wound Reconstruction and Care
83.99M
20.89%
Instruments
50.15M
12.47%
ENT
40.87M
10.16%
Private Label
25.49M
6.34%
By RegionUSD
Name
Revenue
Proportion
United States
295.85M
73.58%
Europe
42.89M
10.67%
Asia Pacific
42.68M
10.62%
Rest of World
20.64M
5.13%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Neurosurgery
201.56M
50.13%
Wound Reconstruction and Care
83.99M
20.89%
Instruments
50.15M
12.47%
ENT
40.87M
10.16%
Private Label
25.49M
6.34%
Shareholding Stats
Updated: Sat, Nov 15
Updated: Sat, Nov 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
11.92%
TRU ST Partnership, L.P.
10.93%
Rubric Capital Management LP
9.83%
The Vanguard Group, Inc.
9.13%
Fuller & Thaler Asset Management Inc.
5.03%
Other
53.16%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
11.92%
TRU ST Partnership, L.P.
10.93%
Rubric Capital Management LP
9.83%
The Vanguard Group, Inc.
9.13%
Fuller & Thaler Asset Management Inc.
5.03%
Other
53.16%
Shareholder Types
Shareholders
Proportion
Investment Advisor
36.64%
Investment Advisor/Hedge Fund
36.54%
Hedge Fund
18.48%
Corporation
10.93%
Individual Investor
3.20%
Research Firm
2.31%
Pension Fund
1.48%
Bank and Trust
0.40%
Sovereign Wealth Fund
0.04%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
583
75.09M
96.41%
-24.67M
2025Q3
583
73.55M
94.42%
-25.07M
2025Q2
600
89.38M
114.72%
-18.72M
2025Q1
635
87.01M
111.97%
-18.30M
2024Q4
636
81.93M
106.10%
-20.27M
2024Q3
638
82.93M
106.93%
-12.58M
2024Q2
628
84.82M
107.92%
-1.75M
2024Q1
613
79.36M
101.18%
-3.69M
2023Q4
597
79.81M
101.26%
-5.74M
2023Q3
592
81.88M
100.31%
-3.94M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
9.29M
11.92%
-146.58K
-1.55%
Sep 30, 2025
TRU ST Partnership, L.P.
8.52M
10.93%
--
--
Feb 28, 2025
Rubric Capital Management LP
7.65M
9.83%
+300.00K
+4.08%
Sep 30, 2025
The Vanguard Group, Inc.
7.29M
9.36%
-217.24K
-2.89%
Sep 30, 2025
Fuller & Thaler Asset Management Inc.
3.91M
5.03%
+21.91K
+0.56%
Sep 30, 2025
Dimensional Fund Advisors, L.P.
3.18M
4.09%
+267.13K
+9.16%
Sep 30, 2025
Invesco Advisers, Inc.
3.18M
4.09%
+3.31K
+0.10%
Sep 30, 2025
State Street Investment Management (US)
2.79M
3.58%
-35.57K
-1.26%
Sep 30, 2025
Boston Management and Research
2.74M
3.52%
--
--
Sep 30, 2025
Paradigm Capital Management, Inc.
2.53M
3.25%
+348.30K
+15.97%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Neuroscience and Healthcare ETF
1.44%
State Street SPDR S&P Health Care Equipment ETF
1.39%
ROBO Global Healthcare Technology & Innovation ETF
1.02%
Invesco S&P SmallCap Health Care ETF
0.49%
Invesco NASDAQ Future Gen 200 ETF
0.43%
Inspire Small/Mid Cap ESG ETF
0.19%
Royce Quant Small-Cap Quality Value ETF
0.13%
Principal U.S. Small-Cap ETF
0.13%
iShares S&P Small-Cap 600 Value ETF
0.12%
State Street SPDR S&P 600 Small Cap Value ETF
0.11%
View more
iShares Neuroscience and Healthcare ETF
Proportion1.44%
State Street SPDR S&P Health Care Equipment ETF
Proportion1.39%
ROBO Global Healthcare Technology & Innovation ETF
Proportion1.02%
Invesco S&P SmallCap Health Care ETF
Proportion0.49%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.43%
Inspire Small/Mid Cap ESG ETF
Proportion0.19%
Royce Quant Small-Cap Quality Value ETF
Proportion0.13%
Principal U.S. Small-Cap ETF
Proportion0.13%
iShares S&P Small-Cap 600 Value ETF
Proportion0.12%
State Street SPDR S&P 600 Small Cap Value ETF
Proportion0.11%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
